scispace - formally typeset
P

Ping Li

Researcher at GlaxoSmithKline

Publications -  34
Citations -  894

Ping Li is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: AS03 & Vaccination. The author has an hindex of 16, co-authored 34 publications receiving 818 citations.

Papers
More filters
Journal ArticleDOI

Safety and Cross-Reactive Immunogenicity of Candidate AS03-Adjuvanted Prepandemic H5N1 Influenza Vaccines: A Randomized Controlled Phase 1/2 Trial in Adults

TL;DR: The AS03-adjuvanted A/Indonesia/05/2005 (NIBRG-14) vaccines were significantly more immunogenic than nonadjuVanted vaccine in homologous assays and fulfilled European and US licensure criteria for immunogenicity for influenza vaccines.
Journal ArticleDOI

Immunogenicity and safety of a tetanus toxoid, reduced diphtheria toxoid and three-component acellular pertussis vaccine in adults 19-64 years of age.

TL;DR: In adult recipients, Tdap3v was comparable to an approved TdAP vaccine in providing seroprotection against diphtheria and tetanus, and produced immune responses to pertussis antigens consistent with protection against disease.
Journal ArticleDOI

Safety and Long-term Humoral Immune Response in Adults After Vaccination With an H1N1 2009 Pandemic Influenza Vaccine With or Without AS03 Adjuvant

TL;DR: A single dose of the 3.75-μg HA AS03(A)-adjuvanted H1N1 2009 influenza vaccine was highly immunogenic in both age strata (18-64 and >64 years), inducing long-term persistence of the immune response until at least 6 months after dose 1.